(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
24 June 2021 (24.06.2021)

WIPO | PCT

(10) International Publication Number
WO 2021/119834 A1

(51) International Patent Classification:
*A61K 31/519* (2006.01) *A61P 35/00* (2006.01)

(21) International Application Number:
PCT/CA2020/051755

(22) International Filing Date:
18 December 2020 (18.12.2020)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
62/949,678 18 December 2019 (18.12.2019) US

(71) Applicant: **UNIVERSITE DE MONTREAL** [CA/CA]; 2900 Edouard-Montpetit, Montréal, Québec H3T 1J4 (CA).

(72) Inventors: **SAUVAGEAU, Guy**; 3110 Chemin St Sulpice, Montréal, Québec H3Y 2B9 (CA). **CHAGRAOUI, Jalila**; c/o IRICOR, Institut de recherche en immunologie et en cancérologie - Commercialisation de la recherche, C.P. 6128, succursale Centre-ville, Montréal, Québec H3C 3J7 (CA). **FORTIER, Simon**; 38 Montée de la Petite Côte, Saint-Mathieu, Québec J0L 2H0 (CA). **GIRARD, Simon**; 427 rue Richard, Longueuil, Québec J4L 3A6 (CA). **MARINIER, Anne**; One Place Baron, Kirkland, Québec H9J 3E9 (CA).

(74) Agent: **NORTON ROSE FULBRIGHT CANADA S.E.N.C.R.L., S.R.L. / LLP**; 2500-1 Place Ville-Marie, Montreal, Québec H3B 1R1 (CA).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,

(54) Title: MODULATORS OF CULLIN 3 ADAPTOR KBTBD4 AS ANTI-CANCER COMPOUNDS





Fig. 15A





Fig. 15B

(57) Abstract: It is provided the use of Pyrimido[4,5-B]indole derivatives as anti-cancer compounds, and more specifically the use of UM171 and its derivatives for treating cancer, by activating the CULLIN3-RING ubiquitin ligase complex which degrades RCOR1 which normally acts as the scaffolding protein for the RCOR1/LSD1 and HDAC2 complex, itself being dissociated in the presence of UM171. Thus UM171 acts like a molecular glue degrader, inhibiting HDACs, RCOR1, CoREST and LSD1 and resulting in an anti-cancer activity.

WO 2021/119834 A1

*[Continued on next page]*

TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

**Declarations under Rule 4.17:**

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

**Published:**

— *with international search report (Art. 21(3))*
— *with sequence listing part of description (Rule 5.2(a))*
— *in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE*